Top 10 Organoid Companies

The past year has witnessed a significant turning point for organoid models, which have emerged as groundbreaking tools for uncovering biological insights that were previously inaccessible through traditional cell culture experiments or animal models. This shift is not only transforming the landscape of biomedical research but also reshaping the regulatory framework governing drug development.

In October, the FDA made history by approving the first-ever investigational new drug (IND) submission that relied solely on human vascularized organoid-based combination studies, without relying on traditional animal efficacy proof-of-concept (POC) testing. This landmark approval was granted to SillaJen, a South Korea-based developer of oncolytic virus immunotherapeutics. This milestone enabled SillaJen to initiate clinical trials for a combination therapy consisting of tislelizumab or paclitaxel and BAL0891, a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK). The Phase I trial, designated as NCT05768932, is currently underway, with its primary completion date estimated at December 24.

SillaJen's IND application included preclinical efficacy data generated through the vascularized tumor immune microenvironment model (vTIME) developed by Qureator. This collaboration between SillaJen and Qureator exemplifies the growing integration of organoid models into drug development pipelines, marking an early example of the shift away from animal testing toward new approach methodologies (NAMs). The FDA's push for this transition was solidified through the FDA Modernization Act 2.0, enacted in 2022. This legislation removed the animal testing requirement for new FDA-regulated products that had been mandated by the Federal Food, Drug, and Cosmetics Act of 1938.

FDA Commissioner Martin A. Makary, MD, highlighted the benefits of this new approach last year, stating, "By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices." Makary emphasized that this shift represents a "win-win" for public health and ethics.

The changing regulatory climate is expected to have a profound impact on the global organoids market. According to recent projections, the market size is poised for significant growth over the next five years, nearly tripling from $1.20 billion in 2022 to $3.29 billion in 2031. This expansion is driven by the increasing adoption of organoid models in both research and drug development, as well as the FDA's support for NAMs.

As the field of organoid research continues to evolve, the top 10 organoid companies are set to play a pivotal role in shaping the future of biomedical science. These companies are not only pioneering innovative organoid models but also contributing to the development of more efficient and ethical drug testing methodologies. With the FDA's endorsement of NAMs and the growing demand for organoid-based research, these companies are well-positioned to lead the charge in unlocking new biological discoveries and accelerating the development of life-saving therapies.

In conclusion, the past year has marked a transformative period for organoid models, with the FDA's approval of the first IND submission supported solely by human vascularized organoid studies serving as a catalyst for change. The collaboration between SillaJen and Qureator, along with the FDA's Modernization Act 2.0, underscores the agency's commitment to advancing NAMs and reducing reliance on animal testing. As the global organoids market is set to grow significantly, the top 10 organoid companies are poised to drive innovation and reshape the landscape of biomedical research and drug development.